



## OREGA Biotech strengthens its intellectual property in Europe

Receipt of two notices of allowance from European Patent Office  
for two strategic patent applications

Lyon, France, July 19, 2016 – OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced today that it has received a notification from the European Patent Office (EPO) stating its intention to grant a patent application filed by OREGA Biotech and related to novel anti-IL-17 antibodies. This patent covers any antibody binding to a functional epitope of IL-17 identified by OREGA Biotech and protects several specific neutralizing antibodies able to bind and inhibit IL-17 homodimer and heterodimer. Based on the date of the priority data, the expected expiration date of this patent is at least until 2032. This notification shortly follows another notice of allowance from the EPO which is about to deliver another strategic patent application held by INSERM and licensed to OREGA Biotech relating to antibodies that bind CD39.

*"The delivery of these two patents is an important milestone in OREGA Biotech's intellectual property strategy. It demonstrates that we are able to generate IP rights over broad claims such as functional epitope or targets and further reinforces our competitive position on our two research programs, interleukin-17 and CD39"*, commented Jeremy Bastid, Chief Operating Officer of Orega Biotech.

As of today, the patent portfolio of the company is composed of 8 families of patent applications owned or co-owned by OREGA biotech and one licensed patent.

### About OREGA Biotech

OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. With a specific focus on tumor microenvironment, OREGA's Target Discovery Program aims at discovering and validating novel clinically-relevant cancer targets.

Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. OREGA's business strategy is to bring its R&D programs up to preclinical proof of concept, IND or early clinical stages and then to license them out to larger biotech or pharmaceutical companies. Funded by initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes Création and INSERM-Transfert Initiative, the company is managed by Gilles Alberici, CEO and Jeremy Bastid, COO.

### Contact

Jeremy Bastid, Chief Operating Officer  
Tel.: +33 (0)4 37 49 87 20  
[jeremy.bastid@orega-biotech.com](mailto:jeremy.bastid@orega-biotech.com)

For more information: [www.orega-biotech.com](http://www.orega-biotech.com)